^
    Evidence Level:
    Sensitive: C3 – Early Trials

    [ROS1 rearrangement-Lung Non-Squamous Non-Small Cell Cancer-crizotinib]

    Source:
    Sci Rep
    Test:

    ZytoLight® SPEC ROS1 Dual Color Break Apart Probe

    Title:
    Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
    Published date:
    10/22/2021
    Excerpt:
    We enrolled 95 non-squamous NSCLC patients with known status of EGFR, ALK, ROS1, MET and RET genes and PD-L1 protein expression….In 32 patients with ALK or ROS1 genes rearrangements, 10 patients received crizotinib and 22 patients chemotherapy in the first-line of treatment. The median overall survival was 34 months (95% CI 9.5–34 months) in crizotinib treated patients and 6 months (95% CI 4–15.5 months) in patients who received chemotherapy (HR = 0.266, 95% CI 0.104–0.678, p = 0.0056)...
    DOI:
    https://doi.org/10.1038/s41598-021-00309-3
    Evidence Level:
    Sensitive: C3 – Early Trials

    [ROS1 rearrangement-Lung Adenocarcinoma-crizotinib]

    Source:
    J Clin Oncol
    Test:

    ZytoLight® SPEC ROS1 Dual Color Break Apart Probe

    Title:
    Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
    Excerpt:
    Thirty patients were evaluable for progression-free survival (PFS), and 29 patients were evaluable for best response....Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1....Crizotinib seems to be the current treatment of choice for ROS1-positive patients.
    DOI:
    10.1200/JCO.2014.58.3302